Valbiotis SA (EPA:ALVAL)
France
· Delayed Price · Currency is EUR 0.708
-0.002 (-0.28%)
At close: Dec 5, 2025
Valbiotis Company Description
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France.
The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis.
The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER.
Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Valbiotis SA
| Country | France |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Sebastien Peltier |
Contact Details
Address: Rue Paul Vatine Périgny, 17180 France | |
| Phone | 33 5 46 28 62 58 |
| Website | valbiotis.com |
Stock Details
| Ticker Symbol | ALVAL |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013254851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sebastien Peltier HDR, Ph.D. | Co-Founder, Chairman of the Management Board and Chief Executive Officer |
| Stanislas Sordet | Chief Financial Officer and Member of Management Board |
| Sebastien Bessy | Chief Operating Officer and Member of the Management Board |
| Pascal Sirvent Ph.D. | CSO and Member of the Management Board |
| Murielle Cazaubiel | CMO and Member of the Management Board |
| Charlotte Jezequel | Director of Human Resources and Member of Management Board |
| Dr. Josep Infesta | Head of Global Business Development |